CAS 2381037-82-5

RBN-2397

CAS: 2381037-82-5

RBN-2397 is a potent, selective and orally active accross species NAD+ competitive PARP7 inhibitor with IC50 less than 3 nM.

Fórmula: C₂₀H₂₃F₆N₇O₃

Pureza: 98.48% - 99.8%

Forma y color: Solid

Peso molecular: 523.43

Ref: TM-T12695

(2S,4S)-1-Boc-4-(4-benzyl-1-piperazinyl)-2-(3,3-difluoropyrrolidine-1-carbonyl)pyrrolidine

CAS: 2381037-82-5

Fórmula: C₂₀H₂₃F₆N₇O₃

Pureza: 98%

Forma y color: Solid

Peso molecular: 523.4321

Ref: IN-DA01KBK1

(S)-5-((1-(3-Oxo-3-(4-(5-(Trifluoromethyl)Pyrimidin-2-Yl)Piperazin-1-Yl)Propoxy)Propan-2-Yl)Amino)-4-(Trifluoromethyl)Pyridazin-3(2H)-One

CAS: 2381037-82-5

(S)-5-((1-(3-Oxo-3-(4-(5-(Trifluoromethyl)Pyrimidin-2-Yl)Piperazin-1-Yl)Propoxy)Propan-2-Yl)Amino)-4-(Trifluoromethyl)Pyridazin-3(2H)-One

Pureza: 98%

Peso molecular: 523.43g/mol

Ref: 54-PC108523

RBN-2397

CAS: 2381037-82-5

RBN-2397

Pureza: ≥98%

Peso molecular: 523.43g/mol

Ref: 54-BUP12710

RBN-2397

CAS: 2381037-82-5

RBN-2397 is a poly-adp-ribose polymerase inhibitor that has been shown to have clinical efficacy in the treatment of cancer. RBN-2397 is a molecule that inhibits the activity of poly-adp-ribose polymerase (PARP), an enzyme involved in the homologous recombination repair of DNA. This inhibition leads to DNA damage and cell death by apoptosis, which are associated with tumor development and progression. RBN-2397 has been shown to be effective as an adjunct therapy for people with metastatic melanoma or other cancers who are resistant to interferon alfa-2b and cytosolic colony stimulating factor.

Fórmula: C₂₀H₂₃F₆N₇O₃

Pureza: Min. 95%

Peso molecular: 523.4 g/mol

Ref: 3D-GVD03782